

1 **Supplementary Information**

2

3 **Adenosine A_{2A} Receptor and ERK Driven Impulsivity Potentiates Hippocampal**

4 **Neuroblast Proliferation**

5

6 Alfredo Oliveros¹, Chang Hoon Cho³, Allen Cui¹, Sun Choi¹, Daniel Lindberg², David
7 Hinton², Mi-Hyeon Jang^{3,4}, and Doo-Sup Choi^{1, 2, 5}

8 ¹Department of Molecular Pharmacology and Experimental Therapeutics, ²Neurobiology
9 of Disease Program, ³Department of Neurologic Surgery, ⁴Department of Biochemistry
10 and Molecular Biology, ⁵Department of Psychiatry and Psychology, Mayo Clinic College
11 of Medicine Rochester, Minnesota 55905, USA.

12

13 Running Title: Adenosine_{A_{2A}}-ERK1/2 Impulsivity Increases Hippocampal-Cell
14 Proliferation

15

16 Correspondence and requests for materials:

17 Doo-Sup Choi, PhD

18 Department of Molecular Pharmacology and Experimental Therapeutics

19 Mayo Clinic College of Medicine


20 200 First Street SW. Rochester, Minnesota 55905, USA

21 Email: choids@mayo.edu, Fax: 507-284-1767, Telephone: 507-284-5602

22

23

24



29

30

31 **Supplementary Figure 2.** Relative to vehicle, C57BL/6J mice administered (*i.p.*) ZM-
 32 241385 does not affect inactive hole entries during (a) DRL-conditioning (n = 5-
 33 6/treatment), (b) non-contingency training (n = 9-10/treatment). (c) There were no
 34 differences detected between the U0126 and vehicle treatment groups in general
 35 activity as measured by inactive-hole responses during conditioning (n = 3-4/treatment).
 36 Unpaired Student's *t*-test. All data are reported as mean ± SEM.

37

38


39

a


Experiment 4-5: vehicle vs. ZM-241385 (*i.p.*)




b




c



d



e





40

41 **Supplementary Figure 3.** (a) Schematic of experimental design for 5-choice serial
42 reaction time task (5-CSRTT) pre-training. (b) Differences in magazine-entries
43 measured during magazine training and 5-hole FR1 training prior were not detected in
44 C57BL/6J mice designated to receive either ZM-241385 or vehicle (*i.p.*) during the
45 5CSRTT. (c) Similarly, aperture entries measured during magazine training and 5-hole
46 FR1 training were not different between mice designated to receive either ZM-241385
47 or vehicle during 5CSRTT testing. (d) There were no differences detected in the number
48 of magazine-entries during 5-CSRTT performance between the treatment groups when
49 mice had to wait for unpredictable reinforcement-associated cues (random internal-time
50 interval). (e) There were no differences between the treatment groups in the number of
51 magazine-entries during 5-CSRTT performance when mice had to wait for predictable
52 reinforcement-associated cues (fixed internal-time interval). **b-c:** n = 5-6/treatment
53 designation, RM-two way ANOVA. **d-e:** n = 5-6/ treatment, unpaired two-tailed Student's
54 *t*-test. All data are reported as mean \pm SEM.

55

56

57


a**b**

58

59 **Supplementary Figure 4.** (a) Open-field analysis was unable to detect differences in
 60 ambulatory velocity in mice treated with ZM-241385 or vehicle (*i.p.*). (b) Distance
 61 traveled was significantly maintained in C57BL/6J mice treated with ZM-241385 relative
 62 to vehicle. **a-b:** n = 9-10/treatment, RM two-way ANOVA. All data are reported as mean
 63 ± SEM.

64


65



66

67 **Supplementary Figure 5.** (a) Analysis of general activity as measured by inactive-hole
 68 responses did not reveal differences between the genotypes during conditioning for
 69 sucrose reward (n = 13-15/genotype). (b) Schematic of experimental design for testing
 70 impulsivity during Pavlovian conditioning. (c) ENT1^{-/-} mice display significantly higher
 71 magazine-entries for sucrose reward during conditioning. (d) In comparison to WT (+/+)
 72 mice, ENT1^{-/-} mice display significantly faster reaction times following CS+
 73 presentations to retrieve a sucrose-ethanol reward during conditioning. (e)
 74 Measurement of inactive-hole entries was not different between the genotypes during
 75 conditioning for sucrose-ethanol reward. All data are reported as mean ± SEM. RM two-
 76 way ANOVA, #p < 0.05 main effect of genotype; *p < 0.05 by Tukey's *post-hoc* multiple
 77 comparisons vs. WT mice. (d-f: n = 6-9/genotype).

78



79

80 **Supplementary Figure 6.** Ethanol self-administration exacerbates goal-tracking
 81 impulsivity. **(a)** Relative to sucrose reward (n = 15), WT (+/+) mice display significantly
 82 higher impulsive magazine-entries for sucrose-ethanol reward during conditioning (n =
 83 9). **(b)** Relative to sucrose reward (n = 13), ENT1^{-/-} mice display significantly higher
 84 impulsive magazine-entries for sucrose-ethanol reward during conditioning. (n = 6). All
 85 data are reported as mean ± SEM. **p* < 0.05 by unpaired two-tailed *t*-test.

86

87

88

89

90

91






92

93

94

95

96

a**b****c****d****e**

97

98 **Supplementary Figure 7. (a)** Schematic of the discrimination task. Operant second-

99 order discrimination training was conducted daily for four days. Discrimination sessions

100 were divided into inter-trial intervals (ITI ≥ 60 s; nosepokes on the non-illuminated

101 active-hole were not reinforced, i.e. extinction), followed by onset of trials (active-hole

102 illumination ≤ 60 s). A nosepoke into the non-illuminated active hole in the last 5 s of the

103 ITI (DRL-5) delayed subsequent trial onset by 5 s. Correct responses (nosepokes

104 during active hole illumination) were signaled by a 0.25 s tone, delivered reinforcement,


105 turned off hole illumination, and began the next ITI. Response omission during a trial

106 turned off illumination and started the next ITI. **(b)** There were no differences between107 WT (+/+) and ENT1^{-/-} mice in active-hole responses for sucrose reward during FR1 pre-108 training. **(c)** During discrimination training, trial completions were not different between109 WT and ENT1^{-/-} mice. **(d)** Relative to WT, ENT1^{-/-} mice displayed significantly higher110 ITI nosepokes on the non-illuminated active-hole. **(e)** In comparison to WT, ENT1^{-/-}

111 mice show impaired discrimination performance as evidenced by a higher ratio of ITI


112 active-hole nosepokes relative to correct nosepokes during trials. All data are expressed

113 as mean ± SEM. Two-way ANOVA, #*p* < 0.05, main effect of genotype **(b):** *n* = 12-114 13/genotype; **c - e:** *n* = 8/genotype).




115

116 **Supplementary Figure 8.** Complete representative immunoblots of main text figures
 117 displaying protein expression in the dorsal hippocampus (dHip). **(a)** Relative to behavior
 118 (beh) naïve vehicle, ZM-241385 administration (*i.p.*) to beh naïve C57BL/6J decreases
 119 expression of phospho-ERK1 ($n = 3/\text{treatment}$) and phospho-ERK2 (see main text) in
 120 the dHip. In contrast, phospho-ERK1 and phospho-ERK2 were significantly higher in the
 121 dHip of mice treated with ZM-241385 which underwent beh conditioning vs. vehicle
 122 treated mice. $n = 4/\text{treatment}$. **(b)** Basal A_{2A}R expression is decreased in the dHip of
 123 beh naïve ENT1^{-/-} mice vs. WT (+/+) mice. $n = 11/\text{genotype}$. **(c)** Relative to beh naïve
 124 WT, beh naïve ENT1^{-/-} mice display decreased expression of phospho-ERK1 ($n =$
 125 3/treatment) and phospho-ERK2 (see main text) in the dHip. In contrast, phospho-ERK1
 126 and phospho-ERK2 was significantly higher in the dHip of beh conditioned ENT1^{-/-} mice
 127 vs. vehicle treated behavior mice. $n = 3/\text{genotype}$. All data are expressed as mean \pm
 128 SEM. * $p < 0.05$ by unpaired two-tailed *t*-test.



129

130 **Supplementary Figure 9.** Complete representative immunoblots of main text figures
 131 displaying protein expression in the nucleus accumbens (NAc). (a) There were no
 132 differences in phospho-ERK1 and phospho-ERK2 (see main text) expression in the
 133 dHip between behavior (beh) naïve vehicle and ZM-241385 treated (*i.p.*) C57BL/6J
 134 mice. There were also no differences detected in phospho-ERK1 and phospho-ERK2
 135 in the dHip of mice treated with ZM-241385 or vehicle following beh conditioning. $n =$
 136 3/treatment. (b) There were no differences in basal A_{2A}R expression in the NAc of beh
 137 naïve ENT1^{-/-} mice vs. WT (+/+) mice. $n = 3-5$ /genotype. (c) There were no differences
 138 in phospho-ERK1 and phospho-ERK2 (see main text) expression in the NAc of behavior
 139 (beh) naïve ENT1^{-/-} mice vs. WT mice ($n = 4$ /genotype). Similarly, there were no
 140 differences detected in phospho-ERK1 and phospho-ERK2 expression in the NAc of
 141 mice treated with ZM-241385 or vehicle following beh conditioning. $n = 3-5$ /genotype. All
 142 data are expressed as mean \pm SEM. * $p < 0.05$ by unpaired two-tailed t -test.



143

144 **Supplementary Figure 10.** Complete representative immunoblots displaying protein
 145 expression in the dorsal hippocampus (dHip) and nucleus accumbens (NAc) from
 146 C57BL/6J mice which underwent non-contingency testing. **(a)** There were no differences
 147 in phospho-ERK1 and phospho-ERK2 expression in the dHip between non-contingency
 148 trained vehicle and ZM-241385 treated (*i.p.*) mice $n = 4/\text{treatment}$. **(b)** Our analysis
 149 detected a significant increase in expression of phospho-ERK1 but not phospho-ERK2
 150 in the NAc of mice that underwent non-contingency training and were administered ZM-
 151 241385 or vehicle. $n = 4/\text{treatment}$. All data are expressed as mean \pm SEM. $*p < 0.05$
 152 by unpaired two-tailed *t*-test.

153

154


155

156

157

158


159



160








161 **Supplementary Figure 11.** Representative immunoblots showing the effects of ethanol
 162 on ERK1/2 phosphorylation in the dorsal hippocampus (dHip). **(a)** Complete immunoblot
 163 showing a lack of differences detected between ENT1^{-/-} mice and WT mice in phospho-
 164 ERK1 and phospho-ERK2 expression in the dHip following DRL-conditioning for
 165 sucrose-ethanol (SE) reward. *n* = 4 mice/genotype. **(b)** Representative immunoblot
 166 showing a significant decrease of phospho-ERK1 and phospho-ERK2 expression in the
 167 dHip of WT (+/+) mice (left) treated (*i.p.*) with ethanol (1.5g/kg) vs. vehicle). *n* =
 168 6/genotype and *n* = 3/treatment. One-way ANOVA, $F_{(3, 11)} = 62.59$, $p < 0.0001$, * $p < 0.01$
 169 by Tukey's multiple comparisons. There was a significant decrease in phospho-ERK1
 170 and phospho-ERK2 expression in the dHip of ENT1^{-/-} mice (right) treated (*i.p.*) with
 171 ethanol (1.5g/kg) vs. vehicle. *n* = 6/genotype and *n* = 3/treatment. One-way ANOVA, F
 172 $_{(3, 11)} = 21.27$, $p < 0.001$, * $p < 0.01$ by Tukey's multiple comparisons. All data are
 173 expressed as mean \pm SEM.

174



175

176 **Supplementary Figure 12.** Phospho-ERK activity in the dorsal hippocampus (dHip)
 177 and nucleus accumbens (NAc) as a result of DRL-conditioning. **(a)** There were no
 178 differences of phospho-ERK1 or phospho-ERK2 expression in the dHip between
 179 behavior naïve vehicle treated mice and DRL-conditioned vehicle treated mice. n = 3-
 180 4/behavioral condition. **(b)** There was a significant increase in expression of phospho-
 181 ERK1 and phospho-ERK2 in the dHip between behavior naïve ZM-241385 treated mice
 182 and DRL-conditioned ZM-241385 treated mice. n = 3-4/behavioral condition. **(c)** There
 183 were no differences in NAc expression of phospho-ERK1 or phospho-ERK2 between
 184 behavior naïve vehicle treated mice and DRL-conditioned vehicle treated mice. n =
 185 3/behavioral condition. **(d)** There was a significant decrease in expression of phospho-
 186 ERK1 and phospho-ERK2 in the NAc between behavior naïve ZM-241385 treated mice
 187 and DRL-conditioned ZM-241385 treated mice. n = 3/behavioral condition. **(e)** There
 188 was a significant decrease in expression of phospho-ERK1 and phospho-ERK2 in the
 189 NAc between behavior naïve WT (+/+) mice and DRL-conditioned WT mice. n =
 190 3/behavioral condition. **(f)** There was a significant increase in expression of phospho-
 191 ERK1 but not phospho-ERK2 in the dHip between behavior naïve ENT1^{-/-} mice and
 192 DRL-conditioned ENT1^{-/-} mice. n = 3/behavioral condition. **(g)** There were no
 193 differences in NAc expression of phospho-ERK1 or phospho-ERK2 between behavior
 194 naïve WT mice and DRL-conditioned WT mice. n = 3-4/behavioral condition. **(h)** There
 195 was a significant increase in expression of phospho-ERK1 but not phospho-ERK2 in the
 196 NAc between behavior naïve ENT1^{-/-} mice and DRL-conditioned ENT1^{-/-} mice. n = 4-
 197 5/behavioral condition. All data are expressed as mean ± SEM. **p* < 0.05 by unpaired
 198 two-tailed *t*-test. N, behavior naïve; C, behavior conditioned.



200 **Supplementary Figure 13.** Expression of markers for cell proliferation and neuroblast
201 development in the dentate gyrus of the dorsal hippocampus (dHip) and ventral
202 hippocampus (vHip) is differentially affected by A_{2A}R inhibition mediated 5-CSRTT
203 impulsivity. **(a)** Representative light microscopy images of the dHip and vHip. **(b)**
204 Representative confocal microscopy images and stereological quantification analysis of
205 BrdU⁺ labeled cells and DCX⁺ indicate significantly higher expression of BrdU⁺ and
206 BrdU⁺DCX⁺ co-labeling in the dHip of 5-CSRTT tested mice administered ZM-241385
207 relative to vehicle. DAPI (blue). Scale bars 100µm. n = 5-6 mice/treatment and n = 3
208 sections/dHip. ***p* < 0.01 by unpaired two-tailed Student's *t*-test. **(c)** Representative
209 confocal microscopy images and stereological quantification analysis of BrdU⁺ and
210 BrdU⁺DCX⁺ co-labeling in the vHip of mice did not detect differences between mice
211 administered ZM-241385 relative to vehicle. Scale bars 100µm. n = 5-6 mice/treatment
212 and n = 3 sections/vHip. **p* < 0.05 by unpaired two-tailed Student's *t*-test. BrdU⁺
213 (green), DCX⁺ (red), DAPI (blue). Subgranular zone (SGZ), Dentate gyrus (DG) of the
214 hippocampus. GCL, Granular cell layer; H, Hilus; ML, Molecular layer. All data are
215 reported as mean ± SEM.

216

217 **SUPPLEMENTARY MATERIALS AND METHODS**

218 **Subjects**

219 ENT1^{-/-} and wild type (WT) mice were generated in house, while C57BL/6J mice were
220 ordered from Jackson Laboratories (Bar Harbor, ME USA). All animals were generated
221 and cared for under a 12 hr/12 hr light-dark cycle with lights on at 06:00 and off at
222 18:00, as previously described^{1,2}. All mice utilized in this study were age-matched 3-
223 to-5 month male mice. A list of all the experimental groups and procedures is depicted
224 in Supplementary Figure 1. All experimental procedures were approved by the Mayo
225 Clinic Institutional Animal Care and Use Committee in accordance with NIH guidelines.

226

227 *Behavior Naïve Mice.* ENT1^{-/-}, WT, and C57BL/6J mice that were naïve to behavior
228 testing and were acutely administered ethanol, or were treated with ZM-241385 (5-
229 days), were group-housed with littermates and maintained in ventilated racks with *ad*
230 *libitum* food and water until ready for brain extraction for subsequent western blot and
231 immunofluorescence analysis as described below (Supplementary Figure 1).

232

233 *Behavior Tested Mice.* Groups tested for Pavlovian conditioning, Fixed Ratio-1 (FR1)
234 training, second-order discrimination, non-contingency training and open-field
235 (Supplementary Figure 1), ENT1^{-/-}, WT, and C57BL/6J mice were individually housed
236 and group housed (see Supplementary Figure 1 for details) and food restricted to reach
237 approximately 85% of their *ad libitum* feeding weight (target weight). For 5-CSRTT pre-
238 training (magazine training, 5-hole FR1 and 5-CSRTT) and 5-CSRTT testing, C57BL/6J
239 mice were group housed and food restricted to reach target weight (Supplementary

240 Figure 1). All subjects were weighed daily and allowed 30 m to acclimate to behavior
241 procedure rooms prior to testing. Immediately following each behavior test, mice were
242 returned to their home cage and fed a daily ration of rodent chow in order to maintain
243 target weight. The behavioral measurements and programming parameters for each
244 behavior test were computer controlled and recorded by Med-PC IV software using
245 Med-State notation (Med-Associates, Inc.). All programs utilized and modified for the
246 experiments in this study can be found at <http://www.mednr.com/index.htm> as part of
247 the MEDstate Notation repository.

248

249 **Drugs**

250 For all experiments involving ZM-241385 (20 mg/kg; *i.p.*, Tocris Bioscience, Bristol, UK),
251 the specific A_{2A}R antagonist was dissolved in 15% DMSO, 15% Cremophor, and in
252 0.9% saline (Sigma-Aldrich, St. Louis MO, USA), at a dose of 0.1ml/10g of body weight.
253 To investigate the effects of acute ethanol administration on protein expression in the
254 dorsal hippocampus (dHip), male ENT1^{-/-} and WT mice were administered an injection
255 of ethanol at a concentration of 1.5 g/kg, *i.p.*; 20% (v/v), dissolved in isotonic saline
256 followed by brain extraction 15 min post injection. To inhibit ERK1/2 in the dHip, the
257 specific MEK inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis (o-
258 aminophenylmercapto) butadiene monoethanolate) was dissolved in 50% DMSO and
259 0.9% saline (Sigma-Aldrich).

260

261 **DRL mediated Pavlovian conditioning**

262 We used Pavlovian and operant conditioning to measure impulsive goal tracking and
263 premature sign-tracking impulsivity^{3,4}. During baseline and Pavlovian conditioning,
264 mice were allowed to freely explore to the operant chamber (MED-307A-B2, Med-
265 Associates, Inc.) with the cubicle fan (CF) and the house light (HL) turned on. Total
266 session time (ST), right and left nosepokes (inactive-holes), and magazine head-entries
267 (magazine-entries) were recorded (ENV-302HD head entry detector, Med-Associates,
268 Inc.). During baseline (30 min), inactive-hole entries (measure of general activity) and
269 magazine entries had no programmed consequences. Following baseline, mice
270 underwent Pavlovian conditioning^{5,6} where they were presented with a random series
271 of tone cues (65dB and 0.25 s in duration; ENV-323HAM, 4500 Hz Sonalert, Med-
272 Associates, Inc.). Each randomly presented tone (CS+) was paired with delivery (PHM-
273 100 syringe pump, Med-Associates, Inc.) of a reward (10 μ l/reward) and recorded by the
274 computer, thus establishing a tone-reward contingency⁷. Acquisition of Pavlovian
275 conditioning was determined by measuring the latency between a CS+ and the next-
276 immediate CS+ evoked magazine entry (CS+ reaction time). The resulting latencies
277 were summed and then divided by the number of CS+ to determine an average reaction
278 time following CS+ presentations.

279 To induce impulsive response behavior, we programmed a DRL schedule into
280 the Pavlovian conditioning task⁸. This schedule utilizes a random time interval between
281 CS+ presentations (the shortest interval being 2 s and the longest being 30 s), so that
282 on average a reward was delivered every 15 s. Any interruption of the magazine entry
283 detector in the absence of a CS+ restarts the time interval before presentation of the
284 next CS+. Session termination was signaled by the HL and CF shutting off, and

285 determined by reaching a pre-defined number of CS+ presentations (as described
286 below). Mice were then immediately placed into their home cage, except on the final
287 testing day where mice were sacrificed immediately following conditioning to isolate the
288 dHip and NAc for western blot analysis.

289

290 *Pavlovian Conditioning and Non-Contingency Experiments.*

291 *Experiment 1.* Group housed C57BL/6J mice (n = 5-6/treatment) received 20% sucrose
292 (maximum of 50 CS+ at 10 μ l/reward) to examine the effects of the specific A_{2A}R
293 antagonist ZM-241385 or vehicle, on impulsivity during Pavlovian conditioning. Mice
294 were injected with ZM-241385 two hours prior to conditioning, as described previously^{2,}
295 ⁹.

296 *Experiment 2. Non-Contingency Training.* To ascertain the effect of A_{2A}R antagonism in
297 the absence of Pavlovian conditioning, group housed C57BL/6J mice (n =
298 10/treatment) were injected with ZM-241385 or vehicle (as described for *Experiment 1*)
299 and randomly presented with a series of neutral stimulus tones (maximum of 40 CS-),
300 with the shortest interval being 5 s and the longest being 90 s, so that on average a CS-
301 was presented every 30 s^{7, 10}, Delivery of non-contingent rewards (20% sucrose + 10%
302 ethanol; maximum of 40) were followed by a series of random time intervals, with the
303 shortest interval being 2 s and the longest being 60 s, so that on average a reward was
304 delivered every 15 s. For this experiment, a DRL schedule was not implemented. Data
305 parameters acquired were identical to *Experiment 1*. Immediately following the final
306 training session, mice were sacrificed and the dHip and NAc were harvested for western
307 blot analysis as described above.

308

309 *Experiment 3.* Group housed C57BL/6J mice (n = 3-4/treatment) underwent baseline
310 and one training day of Pavlovian conditioning (sucrose reward, maximum of 60 CS+ at
311 10 µl/reward) before *ad libitum* feeding in order to prepare for cannulation surgery.
312 Following cannulation surgery and recovery, mice were single housed and directly
313 infused with U0126 or vehicle 30 min prior to DRL-conditioning to test the effects of
314 dampened ERK1/2 phosphorylation on goal-tracking impulsivity. Vehicle and U0126
315 were bilaterally infused (4µg/µL/side) at a rate of 0.5µL/min for a total of 2 min.

316

317 **Operant Conditioning Experiments**

318

319 **5-CSRTT Testing**

320 *5-CSRTT pre-training.* Magazine training and 5-hole FR1 training required for 5-CSRTT
321 acquisition was conducted in five-aperture operant conditioning chambers (MED-NP5M-
322 D1, Med Associates, Inc.). Except for *Habituation*, session duration, aperture
323 responses, and reward magazine entries were recorded for each training stage.

324 *Habituation.* To encourage aperture exploration, 50 µl of reward solution was pipetted
325 into each aperture (L-100 *Pipette-Lite*; Mettler-Toledo International, Inc.) and mice were
326 allowed to explore the chambers for 15 min/day for 2 days. Magazine entries and
327 nose pokes were not recorded. *Magazine Training.* Training (30 m sessions daily/3
328 days) consisted of random illumination of any one of the 5 apertures paired with reward
329 deliveries (20 µl) signaled by illumination of the reward magazine. Reward was
330 available for 5 s after which the reward magazine light and aperture light turned off and

331 the dipper retracted. Between reward deliveries, a random computer controlled ITI
332 consisted of a minimum of 2 s and a maximum of 60 s. After a maximum of 50 reward
333 deliveries, the HL turned off and the session terminated. *5-Hole FR1 Training.* Next,
334 we established an association between the 5-hole apertures and reinforcement delivery.
335 During training sessions, all five nosepoke holes were illuminated and a nosepoke
336 response at any aperture resulted in reinforcement, which required a magazine head
337 entry. Reinforcement was available for a maximum of 5 s, after which the magazine
338 light extinguished and the dipper retracted. Sessions were terminated after 30
339 reinforcements on day 1, and 50 reinforcements on days 2-3.

340

341 *5-CSRTT.* Following FR1 training, we adapted the 5-CSRTT in order to assess
342 impulsive response behavior¹¹. To further assess the effects of A_{2A}R inhibition on sign-
343 tracking impulsivity, we utilized 5-aperture operant conditioning chambers (Med-
344 Associates, Inc.) to test the 5-CSRTT¹¹. Briefly, this task consists of time out intervals
345 (TOI, 5 s) that are followed by trials. Trials are composed of an internal trial-interval
346 (INT-TI) which is followed by random illumination of any one of the 5 apertures within
347 the chamber. A nosepoke into an illuminated aperture or within 5 s following extinction
348 of the aperture light (limited hold) is recorded as a correct trial and results in
349 reinforcement (similar as described for 5-hole FR1). Aperture nosepokes during an
350 INT-TI restarts the INT-TI and is recorded as an impulsive premature response.
351 Similarly, aperture nosepokes during TOIs resets the TOI, delaying trial onset and
352 serves as a measure of impulsivity. A nosepoke on any hole except the illuminated
353 aperture turns off the light, initiates the next trial and is recorded as an incorrect

354 response. Failure to nosepoke into an illuminated or non-illuminated aperture during a
355 trial is recorded as an omission, and initiates the next trial. Sessions were terminated
356 after 30 min or 50 trials had elapsed.

357

358 *Experiment 4.* Group housed C57BL/6J mice were treated with either vehicle (n = 5) or
359 ZM-241385 (n = 6) daily for 5 days. Aperture illumination was fixed at 2 s. For
360 reinforcement, mice had to wait for random (ranged from a minimum of 2 s to a
361 maximum of 60 s) internal time-interval durations (rINT-TI) to expire before nosepoking,
362 thus making reinforcement-associated aperture illuminations unpredictable. TOIs
363 remained constant at 5 s.

364

365 *Experiment 5.* In this experiment, we sought to examine the effects of A_{2A}R antagonism
366 in conjunction with a longer aperture illumination time and a fixed INT-TI. In this
367 experiment, Group housed C57BL/6J mice were treated with either vehicle (n = 5) or
368 ZM-241385 (n = 6) as described for *Experiment 4*. Aperture illumination was gradually
369 shortened from a duration of 10 s (training days 1-2) to 2 s (training days 3-4). For
370 reinforcement, mice had to wait for fixed (5 s) internal time-interval durations (fINT-TI) to
371 expire before nosepoking an illuminated aperture, thus making reinforcement-
372 associated aperture illuminations predictable. TOIs remained constant at 5s.

373

374 *Experiment 6.* WT and ENT1^{-/-} mice (n = 13-15/genotype) received 20% sucrose
375 (maximum of 50 CS+ at 10 µl/reward) during DRL-conditioning. Mice in this experiment

376 were both single housed and group housed. Behavioral programming and data
377 acquisition parameters for *Experiment 6* were identical as described for *Experiment 1*.

378
379 *Experiment 7*. In order to investigate the effects of a more hedonic reward on
380 impulsivity during DRL-conditioning, group housed WT and ENT1^{-/-} mice (n = 6-
381 9/genotype) of 20% sucrose and 10% ethanol (maximum of 60 CS+ at 10 µl/reward).
382 Behavioral programming and data acquisition parameters for *Experiment 7* were
383 identical as described for *Experiment 1*.

384

385 **Second-Order Discrimination.**

386 *FR1 Training*. To test the effects of ENT1 deletion on acquisition of stimulus
387 discrimination (i.e. responses when nosepoke hole was illuminated vs. extinction of
388 responses when the nosepoke hole was not illuminated), single housed WT and ENT1^{-/-}
389 mice (n = 12-13/genotype) first underwent magazine training, and shaping by
390 successive approximation¹² to establish FR1 nosepoke responses for sucrose reward.
391 For FR1 training and discrimination testing (see below), correct active-hole nosepoke
392 responses were paired with a 0.25 s tone, while any responses on the inactive-hole
393 (non-illuminated left nosepoke hole) were recorded but had no programmed
394 consequences.

395

396 *Discrimination Testing*. Following FR1 training, WT and ENT1^{-/-} mice (n = 8/genotype)
397 underwent second-order discrimination^{5, 13}. As depicted in Supplementary Figure 6a,
398 this task consisted of mixed, fixed trials (fixed interval ≤ 60 s, signaled by active-hole

399 illumination), followed by inter-trial intervals (ITI \geq 60 s duration). To assess impulsivity
400 during ITIs, a DRL-5 schedule was implemented so that nosepokes into the non-
401 illuminated active-hole during the last 5 s of the ITI delayed trial onset by 5 s. An FR1
402 response during a trial turned off the illuminated active-hole, delivered reinforcement
403 and started the next ITI. Response omissions during trials turned off active-hole
404 illumination and commenced the next ITI. Using the equation below, we examined
405 responses on the non-illuminated active-hole to determine the extent of extinguished
406 responses during the ITI ¹⁴. Sessions were terminated after 1 hr or after 60 trials.

407

408 Equation 1.

409

$$\frac{\text{Completed FR1 Trials}}{(\text{Completed FR1 Trials} + \text{Responses during ITI})}$$

410

411 *Open-field Testing.* To determine the effects of A_{2A}R antagonism on open field activity,
412 group housed C57BL/6J mice were injected (*i.p.*) with ZM-241385 or vehicle (n = 9-
413 10/treatment) and assessed for average velocity (cm/s) and distance traveled (cm) as
414 previously described ¹⁵.

415

416 **Cannulation and Microinjection Procedure.**

417 For *Experiment 3*, we utilized a double-guided cannulae injection system (C315G(2)-
418 G11/SP; PlasticsOne, Roanoke VA, USA) which included injectors extending 1mm
419 beyond the guide cannulae, a dummy cannula (internal 33ga; guide 26ga) and a cap.
420 Surgeries targeting the dHip (AP: -2.1mm from Bregma; Lateral: \pm 1.8mm, and DV:-

421 1.6mm below the dural surface¹⁶ were performed as previously described¹⁵. Following
422 cannulation surgery, mice were allowed to recover for 6-7 days before starting food
423 restriction weight as described above. To ensure the health of our subjects during
424 conditioning following cannulation surgeries, we used their pre-surgery *ad libitum*
425 feeding weight to calculate their *post-surgery* target weight. Approximately 30 min prior
426 to Pavlovian conditioning, mice were briefly exposed (20-30 s) to isoflurane anesthesia
427 and either vehicle or U0126 (4µg/µL/side) was bilaterally infused with a glass syringe
428 and microinjection pump (CMA Microdialysis, Sweden) at a rate of 0.5µL/min for a total
429 of 2 min. Injections were allowed to diffuse for an additional 2 min before removal of
430 injectors. During the infusions, mice were secured by gently holding the tail and were
431 allowed to ambulate as they recovered from isoflurane anesthesia.

432

433 **Tissue Preparation**

434 *Tissue Extraction for Western Blot and Immunofluorescence.* All mice were subjected
435 to rapid CO₂ inhalation to induce unconsciousness, followed by decapitation and
436 subsequent harvesting of brain for isolation of the dHip and NAc from both hemispheres
437 under a surgical microscope. The extracted tissue was snap-frozen on dry ice and
438 stored at -80°C until it was processed for SDS-PAGE (Criterion, Bio-Rad Laboratories,
439 Hercules CA, USA) and western blotting as described below. For immunofluorescence,
440 mice receiving ZM-241385 or vehicle were injected with BrdU (200mg/kg body weight,
441 *i.p.*) at a dose of 0.1ml/10g of body weight 1h post A_{2A}R antagonist or vehicle treatment,
442 and incubation of BrdU was allowed for 2 h as mice were 1) left in the home cage for
443 behavior naïve mice or 2) as the mice performed 5-CSRTT testing¹⁷. Mice treated with

444 ZM-241385 or vehicle were injected (*i.p.*) with a ketamine (100mg/kg) and xylazine
445 (7mg/kg) mixture at a dose of 0.1ml/10g of body weight to induce unconsciousness prior
446 to perfusion. After perfusion, brains were harvested and placed in 4%
447 paraformaldehyde (1x PBS) for 24 h. Subsequently, fixed brains were cryoprotected by
448 incubation in 30% sucrose, until ready for cryostat slicing.

449 **Western Blot.**

450 We examined basal protein expression of the A_{2A}R (n = 11/genotype) and ERK1/2 (n =
451 3/genotype) in the dHip of naïve ENT1^{-/-} and WT mice. We also examined basal
452 protein expression of the A_{2A}R (n = 3-5/genotype) as well as phosphorylated and total
453 ERK1 and ERK2 (n = 4/genotype) in the NAc of naïve ENT1^{-/-} and WT mice. Likewise,
454 we examined protein expression in the dHip following ZM-241385 in C57BL/6J mice
455 that were naïve to behavior (n = 3/treatment). We also explored changes in expression
456 of phosphorylated and total ERK1 and ERK2 in the dHip following Pavlovian
457 conditioning in ENT1^{-/-} (n = 3), WT (n = 3), and C57BL/6J mice treated with vehicle (n =
458 3) or with ZM-241385 (n = 3) (Supplementary Figure 1). In addition, we investigated
459 changes in expression of phosphorylated and total ERK1 and ERK2 in the NAc
460 following Pavlovian conditioning in ENT1^{-/-} (n = 5), WT (n = 3), and C57BL/6J mice
461 treated with vehicle (n = 3) or with ZM-241385 (n = 3) (Supplementary Figure 1).
462 Furthermore, we examined changes in expression of phosphorylated and total ERK1
463 and ERK2 in the dHip (n = 4/treatment) and the NAc (n = 4/treatment) following non-
464 contingency training in C57BL/6J mice treated with vehicle or with ZM-241385
465 (Supplementary Figure 1).

466 The dHip and NAc from each mouse were homogenized in a Storm 24 magnetic
467 Bullet Blender for 4 min at a speed setting of 4 (Next Advance Inc., Averill Park NY,
468 USA), with 0.5 mm zirconium oxide beads in combination with 50-70 μ l of Cell-lytic MT
469 mammalian tissue extraction reagent (Sigma-Aldrich) containing 50 mM Tris buffer (pH
470 7.4), 2 mM EDTA, 5 mM EGTA, and 0.1% SDS. The homogenization buffer also
471 contained Complete (Roche) protease inhibitor cocktail and phosphatase inhibitor
472 cocktails type II and III (Sigma-Aldrich). Homogenates were then centrifuged at 16,400
473 rpm (4°C) for 15 min and supernatants were collected. Protein concentration from each
474 replicate supernatant was quantified using the Bradford protein assay (Bio-Rad).

475 Brain region replicates from each animal were loaded at 30 μ g and separated on
476 a 4-12% Nu-Page Bis-Tris gel in MOPS buffer (Invitrogen, Carlsbad, CA) at 130 V for 2
477 hr, followed by transfer to a PVDF membrane (Invitrogen) at 30 V for 1 hr. Samples
478 were then immunoblotted overnight at 4°C (5% BSA in 1x TBST) with primary
479 antibodies specific for the A_{2A}R (1:500, 45 kDa; Millipore, Billerica MA, USA), ERK1/2
480 (1:500, 42 and 44 kDa; Cell Signaling Technology Inc., Danvers MA, USA), phospho-
481 ERK1/2 (1:500, 42 and 44 kDa; Cell Signaling), and GAPDH (1:1000, 38 kDa; Millipore).
482 Following three 10 min washes in 1x TBST, respective anti-rabbit and anti-mouse
483 secondary antibodies (1:1000, Millipore) were incubated in 1x TBST with immunoblots
484 for 1 hr at room temperature. Blots were incubated for 5 min with the Super-Signal
485 West Dura Chemiluminescent Substrate (Thermo Scientific, Rockford, IL), developed on
486 a Kodak Image Station 4000R scanner (New Haven, CT). Each immunoblot was
487 exposed to detect chemoluminescence for a minimum of 5 s and not exceeding 30 s, in

488 order to avoid potential exposure saturation. Band optical density quantification was
489 performed using NIH ImageJ software.

490

491 **Immunofluorescence.**

492 We examined expression of markers indicative of cell and neuroblast proliferation
493 (BrdU⁺, MCM2⁺ and DCX⁺) from the whole hippocampal DG (5 sections/brain, 200µm
494 apart from anterior to posterior) in age matched (6-week old) behavior naïve WT and
495 ENT1^{-/-} mice (n = 4-5/genotype). Similarly, we examined the process of neuroblast
496 proliferation (BrdU⁺DCX⁺) in 5-CSRTT tested mice administered with ZM-241385 or
497 vehicle (n = 5-6/treatment). From these behavior tested mice we investigated the whole
498 hippocampus (5 sections/brain, 200µm apart from anterior to posterior) and separately
499 the dHip (3 sections/region, 200µm apart from anterior to posterior) and ventral
500 hippocampus (vHip; 3 sections/region, 200µm apart from anterior to posterior) to assess
501 region specific differences. Sample volumes were determined from these sections and
502 cell density was multiplied by the total volume to yield the absolute cell numbers¹⁷,
503 ¹⁸. Coronal brain sections (40µm thick) from each mouse brain were processed to label
504 proliferating cells with primary antibodies for BrdU⁺ (1:250), MCM2⁺ (BM28;1:500), and
505 neuroblasts in the stage of maturation where doublecortin (DCX⁺;1:500) is expressed.
506 Appropriate secondary antibodies (Cy2, Cy3 and Cy5) were used to detect primary
507 antibodies^{17, 19}. Images were acquired on a LSM 780 confocal system (Zeiss) with X20
508 and X40 objectives using a multi-tile configuration. Stereological quantification of
509 BrdU⁺, BrdU⁺DCX⁺, and BrdU⁺MCM2⁺ cells within the subgranular zone (SGZ) and
510 granule cell layer of the DG were carried out using Zen Blue edition (Zeiss) as

511 previously described^{17,18}. To localize cell nuclei, slices were stained with 4', 6-
512 diaminodino-2-phenylindole (DAPI, 1:5000, Santa Cruz).

513

514

515 **Data and Statistical analysis**

516 *Pavlovian conditioning and non-contingency testing:* For CS+ and CS- reaction times,
517 as well as magazine-entries, we conducted repeated measures two-way ANOVA (RM
518 two-way ANOVA) or two-way ANOVA where appropriate. Inactive-hole responses from
519 each subject were averaged for all training days analyzed with an unpaired two-tailed
520 Student's *t*-test. For comparison of magazine-entries between sucrose and sucrose-
521 ethanol reward for each genotype, magazine-entries were averaged for all training days
522 analyzed with an unpaired two-tailed Student's *t*-test. *Discrimination:* For completed
523 trials, ITI nose pokes and discrimination ratios we used two-way ANOVA. *5-CSRTT:*
524 For magazine-entries, aperture entries, FR1 rewards, and premature nose pokes during
525 5-CSRTT pre-training and 5-CSRTT testing, we used RM two-way ANOVA. For TOI
526 responses, magazine-entries, % correct, % incorrect and % omission trials during 5-
527 CSRTT testing, each subject's performance was averaged for all training days, and
528 compared with unpaired two-tailed Student's *t*-test. *Open field:* Velocity and distance
529 traveled were analyzed with RM two-way ANOVA.

530 For western blot analysis, each lane sample was an individual brain region
531 biological replicate from WT and ENT1^{-/-} mice or vehicle and ZM-241385. Each
532 biological replicate was normalized to its respective GAPDH protein expression. Unless
533 otherwise specified, we utilized an unpaired Student's *t*-test or a one-way ANOVA

534 followed by Tukey's multiple comparisons for western blot analysis. Images are
535 representative of 1-3 Western blotting experiments. For all BrdU⁺, BrdU⁺MCM2⁺, and
536 BrdU⁺DCX⁺ statistical analyses, cell numbers derived from 3-5 coronal sections were
537 averaged for each brain and we utilized an unpaired Student's *t*-test for comparisons.
538 Statistical significances reported for all ANOVA results were followed with Tukey's
539 multiple comparisons where appropriate (Sigma Plot 12.0, Systat Software San Jose
540 CA, USA). Results were considered statistically significant when $p < 0.05$ and are
541 presented as mean and \pm SEM (GraphPad Prism, La Jolla CA, USA).

542

543 **References**

- 544 1. Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T *et al.* The
545 type 1 equilibrative nucleoside transporter regulates ethanol intoxication and
546 preference. *Nat Neurosci* 2004; **7**(8): 855-861.
- 547
548 2. Nam HW, Hinton DJ, Kang NY, Kim T, Lee MR, Oliveros A *et al.* Adenosine
549 transporter ENT1 regulates the acquisition of goal-directed behavior and ethanol
550 drinking through A2A receptor in the dorsomedial striatum. *J Neurosci* 2013;
551 **33**(10): 4329-4338.
- 552
553 3. Flagel SB, Watson SJ, Akil H, Robinson TE. Individual differences in the
554 attribution of incentive salience to a reward-related cue: influence on cocaine
555 sensitization. *Behav Brain Res* 2008; **186**(1): 48-56.
- 556
557 4. Winstanley CA. The utility of rat models of impulsivity in developing
558 pharmacotherapies for impulse control disorders. *Br J Pharmacol* 2011; **164**(4):
559 1301-1321.
- 560
561 5. Keller FS, Schoenfeld WN. *Principles of psychology; a systematic text in the*
562 *science of behavior*. Appleton-Century-Crofts: New York,, 1950, xv, 431 p.pp.
- 563
564 6. Mead AN, Stephens DN. Selective disruption of stimulus-reward learning in
565 glutamate receptor *gria1* knock-out mice. *J Neurosci* 2003; **23**(3): 1041-1048.

- 566
567 7. Rescorla RA. Pavlovian conditioning and its proper control procedures. *Psychol*
568 *Rev* 1967; **74**(1): 71-80.
- 569
570 8. Chance P. *Learning and behavior*. Seventh edition. edn. Thomson and
571 Wadsworth, 2013, xviii, 446 pagespp.
- 572
573 9. Stella SL, Jr., Bryson EJ, Cadetti L, Thoreson WB. Endogenous adenosine
574 reduces glutamatergic output from rods through activation of A2-like adenosine
575 receptors. *J Neurophysiol* 2003; **90**(1): 165-174.
- 576
577 10. Rescorla RA. Probability of shock in the presence and absence of CS in fear
578 conditioning. *J Comp Physiol Psychol* 1968; **66**(1): 1-5.
- 579
580 11. Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending
581 noradrenergic neurones on performance of a 5-choice serial reaction task in rats;
582 implications for theories of dorsal noradrenergic bundle function based on
583 selective attention and arousal. *Behav Brain Res* 1983; **9**(3): 361-380.
- 584
585 12. Boules M, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J *et al*. The
586 neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant
587 behavior in the rat. *Brain Res* 2007; **1127**(1): 90-98.
- 588
589 13. Di Ciano P, Everitt BJ. Neuropsychopharmacology of drug seeking: Insights from
590 studies with second-order schedules of drug reinforcement. *Eur J Pharmacol*
591 2005; **526**(1-3): 186-198.
- 592
593 14. Featherstone RE, McDonald RJ. Dorsal striatum and stimulus-response learning:
594 lesions of the dorsolateral, but not dorsomedial, striatum impair acquisition of a
595 stimulus-response-based instrumental discrimination task, while sparing
596 conditioned place preference learning. *Neuroscience* 2004; **124**(1): 23-31.
- 597
598 15. Vadnie CA, Hinton DJ, Choi S, Choi Y, Ruby CL, Oliveros A *et al*. Activation of
599 neurotensin receptor type 1 attenuates locomotor activity. *Neuropharmacology*
600 2014; **85**: 482-492.
- 601
602 16. Franklin KaP, G. *The Mouse Brain in Stereotaxic Coordinates*. 3 edn. Elsevier
603 Academic: San Diego, 2007.
- 604

605 17. Jang MH, Bonaguidi MA, Kitabatake Y, Sun J, Song J, Kang E *et al.* Secreted
606 frizzled-related protein 3 regulates activity-dependent adult hippocampal
607 neurogenesis. *Cell Stem Cell* 2013; **12**(2): 215-223.

608
609 18. Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice
610 living in an enriched environment. *Nature* 1997; **386**(6624): 493-495.

611
612 19. Bonaguidi MA, Wheeler MA, Shapiro JS, Stadel RP, Sun GJ, Ming GL *et al.* In
613 vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell
614 characteristics. *Cell* 2011; **145**(7): 1142-1155.

615
616
617